Factors Associated With Erectile Dysfunction and the Peyronie's Disease Questionnaire in Patients With Peyronie Disease - 09/09/17
, Ted M. Smith b, Gregory J. Kaufman b, Genzhou Liu c, Faysal A. Yafi d, Wayne J.G. Hellstrom dAbstract |
Objective |
To elucidate patient characteristics that impact symptom-related bother and erectile function in patients with Peyronie disease (PD).
Methods |
A post hoc analysis used data from patients with PD (ie, had PD symptoms ≥12 months and penile curvature deformity of 30-90 degrees) who received ≥1 injection of study medication in 2 phase 3 trials of collagenase clostridium histolyticum (Investigation for Maximal Peyronie's Reduction Efficacy and Safety Study I [n = 417] and Investigation for Maximal Peyronie's Reduction Efficacy and Safety Study II [n = 415]). The Covariance Analysis of Linear Structural Equations procedure was used to estimate the potential relationship of specified variables on the level of distress and erectile dysfunction associated with PD as measured by the Peyronie's Disease Questionnaire and the International Index of Erectile Function, erectile function domain.
Results |
Pain during intercourse (P = .02) and PD bother (P <.0001) had a significant impact on International Index of Erectile Function, erectile function scores. The Peyronie's Disease Questionnaire bother domain score was significantly affected by penile curvature deformity, penile shortening, pain during intercourse, and the presence of plaques (P ≤.0005 for all), with pain during intercourse having the greatest impact (maximum likelihood estimation ± standard error = .496 ± .030; P <.0001). Erectile function did not appear to be directly influenced by the presence of plaques, penile curvature deformity, or penile shortening but was associated with PD bother and penile pain.
Conclusion |
This post hoc analysis provides a conceptual framework through which disease characteristics may impact PD-related bother and erectile function in patients with PD.
Le texte complet de cet article est disponible en PDF.Plan
| Financial Disclosure: Wayne J.G. Hellstrom was a principal investigator on the phase III IMPRESS trial and is currently on the speakers' bureau and advisory board for Endo Pharmaceuticals Inc. Genzhou Liu is an employee of Endo Pharmaceuticals Inc. Gregory J. Kaufman and Ted M. Smith were employees of Endo Pharmaceuticals Inc when the manuscript was initiated. Ted M. Smith owns Endo stock. Ted M. Smith and Gregory J. Kaufman are former employees of Auxilium Pharmaceuticals, Inc. The remaining authors declare that they have no relevant financial interests. |
|
| Funding Support: The IMPRESS-I and IMPRESS-II trials were funded by Auxilium Pharmaceuticals, Malvern, PA, USA. |
Vol 107
P. 155-160 - septembre 2017 Retour au numéro
Article précédent
- Sexual Satisfaction: An Opportunity to Explore Overall Health in Men
- Borja García-Gómez, Eduard García-Cruz, Giorgio Bozzini, Juan Justo-Quintas, Esther García-Rojo, Manuel Alonso-Isa, Javier Romero-Otero
- Defining the Role of Intraoperative Transesophageal Echocardiography During Radical Nephrectomy With Inferior Vena Cava Tumor Thrombectomy for Renal Cell Carcinoma
- Megan P. Kostibas, Vivek Arora, Michael A. Gorin, Mark W. Ball, Phillip M. Pierorazio, Mohamad E. Allaf, Daniel Nyhan, Mary Beth Brady
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?